Maravai Lifesciences Hits New 52-Week High at $7.25

Maravai Lifesciences Holdings, Inc. has reached a significant milestone by hitting a new 52-week high of USD 7.25 on July 17, 2026. This achievement marks a notable moment for the small-cap company operating within the Pharmaceuticals & Biotechnology industry. Despite this recent uptick, Maravai's one-year performance reflects a decline of 14.12%, contrasting sharply with the S&P 500's gain of 18.43% over the same period. The company's market capitalization stands at USD 735 million, categorizing it as a micro-cap entity. Financial metrics reveal that Maravai is currently loss-making, with a return on equity of -43.31%. The company's debt-to-equity ratio is 0.39, indicating a moderate level of leverage. Additionally, Maravai does not offer a dividend yield, and its price-to-book ratio is 3.46. This recent price movement underscores the dynamic nature of Maravai Lifesciences Holdings, Inc. within the competitive landscape of the pharmaceuticals and biotechnology sector.